Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. DMI-9523 (Ampion) for moderate to severe osteoarthritis of the knee. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Osteoarthritis is the most common type of arthritis in the UK and leads to painful and stiff joints. Osteoarthritis can affect any joint, but commonly affects knee joints. Daily routine activities can become difficult for patients with osteoarthritis of the knee.
There is no cure for osteoarthritis of the knee but there are treatments which help to reduce the pain. In cases where treatment does not work, knee surgery may be offered.
Ampion is a new drug for the treatment of osteoarthritis of the knee given as an injection into the affected joint. Some studies have suggested that Ampion may help in reducing knee pain in patients who have osteoarthritis of the knee.
If Ampion is licensed for use in the UK, it could be a new treatment option for patients with osteoarthritis of the knee which may improve patient quality of life better than existing treatments. Indexing Status Subject indexing assigned by CRD MeSH Humans; Knee; Knee Joint; Osteoarthritis; Osteoarthritis, Knee Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000530 Date abstract record published 15/03/2016 |